Skip to main content

Table 1 Risk factor associate with pyrazinamide resistance among 110 MDR isolates

From: Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China

Characteristics

No.(%) of isolates

No.(%) of isolates

χ2

P _value

  

PZAR

PZAS

  
 

(n = 110)

(n = 65)

(n = 45)

  

Sex

 Male

77 (70.0)

41 (63.1)

36 (80.0)

0.057

 Female

33 (30.0)

24 (36.9)

9 (20.0)

3.626

Age group

 <30

19 (17.3)

9 (13.9)

10 (22.2)

 30–59

61 (55.4)

37 (56.9)

24 (53.3)

1.047

0.306

  ≥ 60

30 (27.3)

19 (29.2)

11 (24.5)

1.211

0.271

Permanent resident

 Yes

58 (52.7)

38 (58.5)

20 (44.5)

 No

52 (47.3)

27 (41.5)

25 (55.5)

2.096

0.148

Treatment history

 New case

45 (40.9)

21 (32.3)

24 (53.3)

 Re-treated

65 (59.1)

44 (67.7)

21 (46.7)

4.863

0.027

Treatment outcome

 Successful

42 (38.2)

19 (29.2)

23 (51.1)

 Poor

68 (61.8)

46 (70.8)

22 (48.9)

5.393

0.020

Cavity

 Yes

65 (59.1)

39 (60.0)

26 (57.8)

 No

45 (40.9)

26 (40.0)

19 (42.2)

0.054

0.816

Initial sputum smear

 Negative

7 (6.4)

6 (9.2)

1 (2.2)

 Positive

103 (93.6)

59 (90.8)

44 (97.8)

2.192

0.279

Genotype

 Non-Beijing family

23 (20.9)

14 (21.5)

9 (20.0)

 Beijing family

87 (79.1)

51 (78.5)

36 (80.0)

0.038

0.845

PncA gene mutation

 Yes

56 (50.9)

54 (83.1)

2 (4.4)

 

 No

54 (49.1)

11 (16.9)

43 (95.6)

65.787

0.000

Resistance to

 SM

65 (59.1)

44 (67.7)

21 (46.7)

4.863

0.027

 EMB

52 (47.3)

37 (56.9)

15 (33.3)

5.937

0.015

 OFLX

33 (30.0)

28 (43.1)

5 (11.1)

12.939

0.000

 LVX

33 (30.0)

28 (43.1)

5 (11.1)

12.939

0.000

 KAN

9 (8.2)

6 (9.2)

3 (6.7)

0.233

0.898

 AMK

8 (7.3)

6 (9.2)

2 (4.4)

0.903

0.564

 CAP

4 (3.6)

2 (3.1)

2 (4.4)

0.142

1.000

 PTO

2 (1.8)

1 (1.5)

1 (2.2)

0.070

1.000

 PAS

6 (5.5)

1 (1.5)

5 (11.1)

4.725

0.081

 Pre-XDR

32 (29.1)

25 (38.5)

7 (15.6)

6.764

0.009

 XDR

7 (6.4)

6 (9.2)

1 (2.2)

1.174

0.279

  1. Abbreviations: R, resistant; S susceptible; SM, streptomycin; EMB, ethambutol; OFX, ofloxacin; LFX, levofloxacin; KAN, kanamycin; AMK, amikacin; CAP, capreomycin; PTO, protionamide; PAS, para-amino salicylic acid; Pre-XDR, pre-extensively extensive drug resistance; XDR, extensive drug resistance